3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
70
Neoplasms
13
Neoplasm Metastasis
7
Brain Neoplasms
7
Head and Neck Neoplasms
6
Breast Neoplasms, Male
6
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Osteitis Deformans
2
Neuroma, Acoustic
2
Neurofibromatosis 2
2
Inflammatory Breast Neoplasms
2
Glioblastoma
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Ependymoma
2
Colorectal Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Hepatocellular
2
Bile Duct Neoplasms
2
Interventions
Temozolomide
47
Bevacizumab
41
Radiotherapy
17
Magnetic Resonance Spectroscopy
14
Irinotecan
11
Nivolumab
8
Everolimus
7
Radiation
6
poly ICLC
5
X-Rays
5
Phantoms, Imaging
5
Carboplatin
5
pembrolizumab
4
fluorodopa F 18
4
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Erlotinib Hydrochloride
4
Carmustine
4
ribociclib
3
palbociclib
3
ivosidenib
3
antineoplaston A10
3
Vorinostat
3
Radiotherapy, Intensity-Modulated
3
Radiosurgery
3
Modafinil
3
Lomustine
3
Biopsy
3
veliparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Glioma
×
Lapatinib
×
Clear all
NCT00350727
2013-04-19
VEG102857
GlaxoSmithKline
Phase 2
Completed
75 enrolled
45 charts